Quantcast

David Ebersman Joins Ironwood Board of Directors

September 14, 2009

CAMBRIDGE, Mass., Sept. 14 /PRNewswire/ — Ironwood Pharmaceuticals, Inc. today announced that David Ebersman has joined the Company’s Board of Directors. Mr. Ebersman is the chief financial officer of Facebook. He served at Genentech from 1994-2009 in a number of senior positions, including executive vice president and chief financial officer, senior vice president of product operations, vice president of product development, and project team leader for Avastin((R)), Genentech’s breakthrough cancer therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081006/NEM080ALOGO )

“We are thrilled to have David join our board. He is owner-oriented, exceptionally strategic, and committed to fostering an environment with a high degree of integrity. He also brings broad industry experience that will enrich our Board deliberations,” said Peter Hecht, CEO of Ironwood.

“I share the Ironwood team’s passion for delivering important new medicines to patients,” said Mr. Ebersman. “I am excited to contribute to Ironwood’s efforts to build a great and enduring business.”

Mr. Ebersman has an A.B. in economics and international relations from Brown University and is a fellow in the Henry Crown Fellowship Program.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (www.ironwoodpharma.com) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, the Company’s first-in-class compound, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood has raised $306 million in private equity financing and is located in Cambridge, Massachusetts.

    Contact:
    Susan Brady
    Corporate Communications
    617.621.8304
    sbrady@ironwoodpharma.com

SOURCE Ironwood Pharmaceuticals, Inc.


Source: newswire



comments powered by Disqus